Back to Biomarkers List
Associated Genetic Biomarkers
RB1 Frameshift serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains RB1 Frameshift as an inclusion criterion, 1 is phase 2 (1 open).
Trials with RB1 Frameshift in the inclusion eligibility criteria most commonly target endometrial endometrioid adenocarcinoma, glioblastoma, leiomyosarcoma, non-small cell lung carcinoma, and prostate adenocarcinoma .
Abemaciclib, apalutamide, bevacizumab, cetrelimab, and everolimus are the most frequent therapies in trials with RB1 Frameshift as an inclusion criteria .
Significance of RB1 Frameshift in Diseases
Prostate Adenocarcinoma +
RB1 is altered in 5.19% of prostate adenocarcinoma patients .
RB1 Frameshift is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Frameshift and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.